Lee Yuno, Kim Songmi, Kim Jun Young, Arooj Mahreen, Kim Siu, Hwang Swan, Kim Byeong-Woo, Park Ki Hun, Lee Keun Woo
Division of Applied Life Science (BK21 Program), Systems and Synthetic Agrobiotech Center (SSAC), Plant Molecular Biology and Biotechnology Research Center (PMBBRC), Research Institute of Natural Science (RINS), Gyeongsang National University (GNU), Jinju, Republic of Korea.
PLoS One. 2014 Jan 21;9(1):e85827. doi: 10.1371/journal.pone.0085827. eCollection 2014.
Stilbene urea derivatives as a novel and competitive class of non-glycosidic α-glucosidase inhibitors are effective for the treatment of type II diabetes and obesity. The main purposes of our molecular modeling study are to explore the most suitable binding poses of stilbene derivatives with analyzing the binding affinity differences and finally to develop a pharmacophore model which would represents critical features responsible for α-glucosidase inhibitory activity. Three-dimensional structure of S. cerevisiae α-glucosidase was built by homology modeling method and the structure was used for the molecular docking study to find out the initial binding mode of compound 12, which is the most highly active one. The initial structure was subjected to molecular dynamics (MD) simulations for protein structure adjustment at compound 12-bound state. Based on the adjusted conformation, the more reasonable binding modes of the stilbene urea derivatives were obtained from molecular docking and MD simulations. The binding mode of the derivatives was validated by correlation analysis between experimental Ki value and interaction energy. Our results revealed that the binding modes of the potent inhibitors were engaged with important hydrogen bond, hydrophobic, and π-interactions. With the validated compound 12-bound structure obtained from combining approach of docking and MD simulation, a proper four featured pharmacophore model was generated. It was also validated by comparison of fit values with the Ki values. Thus, these results will be helpful for understanding the relationship between binding mode and bioactivity and for designing better inhibitors from stilbene derivatives.
作为一类新型且具有竞争力的非糖苷类α-葡萄糖苷酶抑制剂,二苯乙烯脲衍生物对治疗II型糖尿病和肥胖症有效。我们分子建模研究的主要目的是通过分析结合亲和力差异来探索二苯乙烯衍生物最合适的结合姿态,并最终开发出一个能够代表α-葡萄糖苷酶抑制活性关键特征的药效团模型。通过同源建模方法构建了酿酒酵母α-葡萄糖苷酶的三维结构,并将该结构用于分子对接研究,以找出活性最高的化合物12的初始结合模式。对初始结构进行分子动力学(MD)模拟,以在化合物12结合状态下对蛋白质结构进行调整。基于调整后的构象,通过分子对接和MD模拟获得了二苯乙烯脲衍生物更合理的结合模式。通过实验Ki值与相互作用能之间的相关性分析验证了衍生物的结合模式。我们的结果表明,强效抑制剂的结合模式涉及重要的氢键、疏水和π相互作用。通过对接和MD模拟相结合的方法获得了经过验证的化合物12结合结构,生成了一个合适的四特征药效团模型。还通过将拟合值与Ki值进行比较对其进行了验证。因此,这些结果将有助于理解结合模式与生物活性之间的关系,并有助于从二苯乙烯衍生物设计出更好的抑制剂。